Spiro Therapeutics announces the appointment of Kamal Hamed, MD, MSc in Public Health, and MBA, as Chief Medical Officer

Spiro Therapeutics Inc.

Dr. Hamed has greater than 20 years of expertise in an infection management and has led the worldwide improvement and approval of many anti-infective merchandise.

CAMBRIDGE, MA, Sep 15, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO) right this moment introduced the appointment of Kamal Hamid, MD, MPH, MBA, as Medical Director (CMO).

“Kamal joins Spero with a confirmed monitor document of constructing and main profitable an infection management franchises,” mentioned Ankit Mahadevya, MD, CEO of Spero Therapeutics. “This, mixed with a singular mixture of expertise within the biotechnology trade, in world pharmaceutical corporations, and as an infectious illness doctor, makes him the best candidate to affix Spero in a CMO place. I’m delighted to have Kamal on our administration workforce and sit up for working collectively.”

Dr. Hamed has greater than 20 years of expertise main a number of medical anti-infective improvement applications in antibacterials, antivirals, antimalarials and antifungals. Previous to becoming a member of Spero, he was Chief Advertising Officer at Lysovant Sciences, a subsidiary of Roivant Sciences. Previous to his work at Lysovant, Dr. Hamed was Head of Scientific Growth and Scientific Affairs at Basilea Pharmaceutica. Earlier in his profession, he held senior medical improvement and medical positions at Novartis (together with Head of Antiinfective Therapeutic Space), Bristol-Myers Squibb, and Bayer, the place he led profitable world improvement, approval, and post-marketing medical assist for quite a few anti-infective merchandise.

Previous to becoming a member of the pharmaceutical trade, Dr. Hamed labored as an instructional doctor for 14 years. He holds a grasp’s diploma in medication from the American College of Beirut, a grasp’s diploma in public well being from Johns Hopkins College, and a grasp’s diploma in enterprise administration from the College of South Florida. Dr. Hamid accomplished a residency in inner medication at UMDNJ – Robert Wooden Johnson Faculty of Medication and a fellowship in Infectious Illnesses at Stanford College Faculty of Medication. He’s a fellow of each the American School of Physicians and the Infectious Illnesses Society of America and has revealed greater than 110 manuscripts in peer-reviewed journals.

Dr. Hamed commented, “The chance to steer the event of Spiro’s pipeline applications is thrilling, as each targets an pressing, unmet want within the antibiotic house. If profitable, these applications may present clear advantages, not only for sufferers, however for the whole healthcare system. Spiro’s lead candidate, SPR720, has the potential to be the one first-line oral remedy for non-tuberculous fungal lung illness.SPR206 could possibly present a brand new therapeutic mannequin for multidrug-resistant Gram-negative infections.Lastly, tebipenem HBr has confirmed to be worthy of continued examine and improvement. medical, given the dimensions of the marketplace for advanced urinary tract infections and unmet affected person wants.”

About Spiro therapeutic
Spero Therapeutics is a multi-asset, medical stage biopharmaceutical firm centered on figuring out, creating and commercializing new remedies for bacterial infections, together with multidrug-resistant bacterial infections and uncommon illnesses.

  • Spiro Therapeutics is creating SPR720 as a brand new oral remedy candidate for the therapy of a uncommon orphan lung illness attributable to non-tuberculous mycobacterium an infection.

  • Spero Therapeutics additionally has a next-generation intravenously administered polymyxin product candidate, SPR206, developed from its strong platform, which is in improvement for the therapy of multidrug-resistant Gram-negative infections within the hospital setting.

  • Tebipenem HBr is an experimental drug in the US being developed to deal with pyelonephritis, together with pyelonephritis, attributable to sure microorganisms, in grownup sufferers with restricted therapy choices; tebipenem HBr isn’t FDA permitted.

For extra info go to https://sperotherapeutics.com.

forward-looking statements
This press launch could include forward-looking statements. These statements embrace, however should not restricted to, statements concerning the potential regulatory path ahead for tebipenem HBr and the potential approval of tebipenem HBr by the Meals and Drug Administration and the timing thereof; The potential worth of tebipenem HBr; future improvement and commercialization of SPR720, SPR206 and tebipenem HBr; design, initiation, timing, progress, and outcomes of preclinical research and medical trials of Spiro and its analysis and improvement applications; and administration analysis of the outcomes of such preclinical research and medical trials. In some circumstances, forward-looking statements could also be recognized by phrases equivalent to “could,” “will,” “ought to,” “count on,” “plan,” “goals,” “count on,” “may,” “intent,” “goal,” undertaking”, “suppose”, “consider”, “estimate”, “predict”, “probably” or “go on” or the passivity of those or different related phrases. Precise outcomes could differ materially from these indicated in such statements forward-looking outcomes on account of a number of essential elements, together with whether or not the FDA will ultimately approve tebipenem HBr and, if that’s the case, the timing of any such approval; whether or not the FDA would require any extra medical information or impose restrictions on the labeling of tebipenem HBr use that may add prices for Spero, delay approval, and/or cut back the industrial prospects for tebipenem HBr; whether or not any third celebration could be interested by partnering with Spero to pursue ongoing efforts to acquire FDA approval for tebipenem HBr, or Acquisition of the rights to the tebipenem HBr program from Spero by way of a partnership association; COVID-19 pandemic; Hajj Spiro for extra funding; threat of Spero not having the ability to deal with FDA considerations relating to tebipenem HBr; The prolonged, costly, and unsure medical drug improvement course of for SPR720 and SPR206; whether or not outcomes obtained in preclinical research and medical trials are indicative of outcomes obtained in future medical trials; Spero’s reliance on third events to fabricate, develop and commercially market its candidate merchandise, if permitted; The power to market Spero candidate merchandise, if permitted; Spiro’s capacity to retain key staff; whether or not Spiro’s financial sources can be adequate to fund its persevering with operations for the anticipated intervals and/or trials; and different elements mentioned within the “Danger Components” set forth within the filings that Spero makes periodically with the US Securities and Change Fee. Ahead-looking statements contained on this press launch symbolize Spero’s views as of the date of this press launch. Spero anticipates that subsequent occasions and developments will result in a change in her views. Nonetheless, whereas Spero could select to replace these forward-looking statements sooner or later sooner or later, it particularly disclaims any obligation to take action. These forward-looking statements shouldn’t be relied upon as representing Spero’s views as of any date later than the date of this press launch.

Investor Relations Contact:
Ted Jenkins
Vice President, Investor Relations and Strategic Finance
TJenkins@sperotherapeutics.com
(617) 798-4039

Media inquiries: media@sperotherapeutics.com

Related Posts